To compare the addition of weekly dulaglutide vs the addition of placebo to titrated glargine in patients with type 2 diabetes (T2D) with sub-optimum glycated haemoglobin (HbA1c) concentration.
| INTRODUCTION
In type 2 diabetes (T2D), the addition of insulin or glucagon-like peptide-1 receptor agonists (GLP-1RAs) is needed when oral antihyperglycaemia medications do not maintain adequate glycaemic control. Titrated basal insulin glargine added to oral antihyperglycaemia medication therapy is a common approach to the initiation of injectable therapy 1, 2 ; however, many patients are unable to achieve glycaemic targets and, in those who do, hypoglycaemia risk increases, 3 and weight gain is common. 3, 4 Treatment with basal insulin often provides initial glycaemic improvements, but subsequent deterioration occurs in most patients, requiring further insulin dose uptitration. 5, 6 Interest in the addition of GLP-1RAs to basal insulin therapy has recently increased as a result of their complementary effects on glycaemic control and their ability to increase satiety and induce weight loss. 7 GLP-1RAs may also lead to a reduction in insulin dose by enhancing endogenous insulin secretion, which may contribute to the beneficial effects on body weight and hypoglycaemia risk. 8 Combination therapy can be administered using separate preparations of each component (flexible-dosing strategy) or using combination preparations containing both agents (fixed-ratio strategy). [9] [10] [11] Twice-daily exenatide combined with titrated glargine improved glycaemic control with modest weight loss and without increasing hypoglycaemia risk vs placebo. 10, 11 Similar results were observed with once-daily lixisenatide or once-weekly albiglutide 12, 13 and with fixed combinations of insulin degludec and liraglutide or glargine and lixisenatide. 14, 15 The flexible combination regimen with basal insulin and onceweekly GLP-1RAs is of interest because it reduces the number of injections compared with combinations with once-or twice-daily GLP-1RAs, thus decreasing treatment burden. The AWARD-9
(Assessment of Weekly AdministRation of LY2189265 [dulaglutide] in Diabetes-9) study compared the addition of dulaglutide vs the addition of placebo to glargine, titrated to target. While there have been previous trials conducted with the combination of weekly GLP-1RA and basal insulin therapy, 13 this was the first study to employ intensive insulin dose titration in both arms using the treat-to-target (TTT) algorithm. The study regimens were assessed with respect to their effects on glycaemic control, body weight and relevant safety outcomes during a 28-week treatment period. Because of scarcity of data on patient-reported outcomes measures (PROMs) with the combination regimen, we assessed several PROMs.
| MATERIALS AND METHODS

| Study design and participation
This phase III, multicentre, double-blind, parallel-arm, placebocontrolled study compared the safety and efficacy of dulaglutide 1.5 mg with placebo, when both were added to daily insulin glargine titrated to target. Patients were randomized 1:1 to receive weekly subcutaneous injections of dulaglutide 1.5 mg or placebo with glargine according to a computer-generated random sequence using an interactive voice response system. Adults with T2D (glycated haemo- to randomization) and a treatment period (28 weeks from randomization to the study end, including a 4-week stabilization phase, followed by a 24-week titration phase). During the lead-in period, patients were required to provide self-monitored plasma glucose (SMPG) measurements; only patients who required an increase in glargine dose at randomization as a result of fasting plasma glucose (FPG) above the target as per the TTT algorithm were eligible (Table S1 ). 1 The study was conducted in accordance with the Declaration of
Helsinki and Council for International Organizations of Medical
Sciences International Ethical Guidelines, as well as the International
Conference on Harmonisation Good Clinical Practices Guideline. The protocol was approved by local institutional review boards. All patients provided written informed consent prior to any procedure.
The study was registered with ClinicalTrials.gov (NCT02152371).
| Procedures
During the lead-in period, insulin dose assessments occurred once weekly and insulin doses were adjusted according to the algorithm only when needed to prevent the occurrence of hypoglycaemia or severe hyperglycaemia. After randomization, during the initial 4-week stabilization phase, insulin dose was assessed twice weekly. The glargine dose remained unchanged if the baseline HbA1c concentration was >8.0% or was decreased by 20% if HbA1c was ≤8.0% immediately after randomization to avoid hypoglycaemia in patients receiving dulaglutide. Additional insulin dose adjustments during this phase were required only in case of the occurrence of hypoglycaemia or severe hyperglycaemia. After the stabilization phase, the insulin dose was adjusted without limitations in both arms until the trial end.
Office visits during the treatment period were weekly or bi-weekly during the first 2 months and thereafter every 4 to 6 weeks.
Compliance with treatment regimen was assessed by: (1) administration of study drug at every visit; patients were considered compliant if taking at least 75% of the required doses; and (2) compliance with the TTT algorithm after 6, 8 and 12 weeks of therapy, measured by the proportion of assessments performed correctly, the proportion of assessments that required a dose change, and the proportion of assessments for which the required dose changes were correctly followed.
Patients requiring an additional intervention as a result of severe, persistent hyperglycaemia were to stop the study drug and discontinue the study after the early termination visit. Patients who discontinued the study drug for any other reason were also required to discontinue the study at the same time.
| Outcomes
The primary objective was to demonstrate superiority of addition of dulaglutide over the addition of placebo to insulin glargine titrated to target with regard to change in HbA1c from baseline to week 28. The hypoglycaemia rate and incidence of documented symptomatic, asymptomatic, probable symptomatic, severe, nocturnal and total hypoglycaemia were also assessed (see Appendix S1). Total hypoglycaemia included severe, documented symptomatic, asymptomatic or probable symptomatic events, defined as plasma glucose ≤3.9 mmol/L, 16 and unspecified hypoglycaemia. Severe hypoglycaemia was defined as an event that required the assistance of another person to actively administer therapy.
Patients' quality of life was assessed with regard to PROMs at baseline and weeks 12 and 28 using various questionnaires.
The EQ-5D-5 L assessed the patient's health status related to mobility, self-care, usual activities, pain/discomfort, and anxiety/ depression 17 ; the 18-item Diabetes Health Profile (DHP-18) questionnaire assessed psychological distress, barriers to activity, and disinhibited eating, and included disease-specific health-related quality of life questions adapted for use in patients with T2D 18 ;
the Impact of Weight on Self-Perception (IW-SP) questionnaire was used to assess how often body weight affected patient happiness with his/her appearance and how often the patient felt self-conscious in public. 19 The modified Medication Delivery Device Assessment Battery (MDDAB), assessed at baseline and weeks 6 and 28, evaluated patient perceptions regarding the use of the dulaglutide and placebo injection devices (identical in both arms). 
| RESULTS
Overall, 300 patients were randomized to dulaglutide 1. (Table 1) .
| Efficacy
Least squares (LS) mean AE s.e. changes from baseline in HbA1c were ≤6.5% (≤48 mmol/mol) vs placebo/glargine (16.7%) at 28 weeks (P < .001, both comparisons; Figure 2B ).
Significant decreases from baseline in FSG and plasma glucose from the 7-point SMPG profiles were observed with both dulaglutide 1.5 mg and placebo at 28 weeks (P < .001, both treatment arms for each variable). Dulaglutide/glargine treatment reduced FSG (P < .001; Figure 2C ) and plasma glucose from the 7-point SMPG profiles at 28 weeks significantly more than placebo/glargine (P ≤ .007; Figure 2D and Table S2) A summary of results of assessments of composite outcomes is presented in Table S3 . A significantly greater percentage of patients achieved HbA1c <7.0% (<53 mmol/mol) without weight gain at 28 weeks and/or documented symptomatic hypoglycaemia during the maintenance period in the dulaglutide/glargine group than in the placebo/glargine group (P < .001, all comparisons).
The LS mean AE s.e. increases from baseline in daily glargine dose were significantly smaller with dulaglutide/glargine (13 AE 2 U Figure S1C ). Figure S3 and (Table S5 ). Approximately 90% of the assessments in both groups were performed correctly.
Approximately 43% and 17% of patients in both groups did not follow assessment outcomes 1 or more times as a result of patient or investigator decision, respectively. The most frequent reason for physician and patient decision not to follow the algorithm was hypoglycaemia (approximately 25% and 11% of patients overall, respectively; no significant differences between the groups).
Significant improvements in PROMs were observed with dulaglutide/glargine for the IW-SP Transformed Total Score (LS mean difference 6.06; P = .019) and the DHP-18 Disinhibited Eating Domain
Transformed Score (LS mean difference −4.50; P = .017) vs placebo/ glargine at 28 weeks. There were no differences for other PROMs.
The majority of patients (95%) reported that the dulaglutide injection device was "easy" or "very easy." The device features that were rated highest by the patients were those related to features of the needle (ie, not having to touch the needle, not having to attach the needle, and automatic insertion). Approximately 90% of patients were satisfied with their overall injection experience with the dulaglutide and placebo injection devices at 28 weeks.
| Safety
Nine patients (6.0%) in the dulaglutide/glargine group and 7 (4.7%) in the placebo/glargine group experienced serious AEs (Table S6) Figure S1D and Table S7 p-amylase were 24% AE 3% vs 8% AE 2% and 23% AE 3% vs 9% AE 2% for dulaglutide/glargine vs placebo/glargine, respectively (Table 2) . Changes in total amylase were smaller but consistent with changes in p-amylase levels. There were no reports of C-cellrelated AEs. Changes from baseline in median calcitonin values did not significantly differ.
No dulaglutide/glargine-treated patients developed treatmentemergent anti-drug antibodies (Table 2) . Three patients reported
TEAEs possibly related to a hypersensitivity reaction (dulaglutide/ glargine, n = 2 [pruritus and allergic pruritus]; placebo/glargine, n = 1
[pruritus and erythaema]) that were all mild to moderate in intensity.
Only the allergic pruritus was considered related to study drug by the investigator. A single TEAE related to injection site reaction was reported in the dulaglutide/glargine group (injection site haematoma).
| DISCUSSION
Combining agents from different glucose-lowering medication classes to improve glycaemic control and/or minimize side effects is the recommended approach to treat T2D. 22 In the present trial, we design. Patients in the placebo/glargine group increased insulin doses more than those in the dulaglutide/glargine group during this phase, with significant differences achieved between weeks 12 and 18. We observed only modest and similar changes in both groups thereafter until the trial endpoint at week 28. Consistent with data for insulin doses, most of the effect on FPG was obtained after 12 weeks of therapy (Table S2 ), suggesting that the duration of the treatment period was appropriate for planned assessments in AWARD-9. We also assessed insulin dosing and FSG control for patients with and without 20% insulin dose adjustment after randomization (Table S4 and Figure S3 ). These data showed that patients who required a 20%
insulin dose decrease at randomization (approximately one-third of the patients in each treatment group) were able to adjust their insulin dose in a timely manner and achieve most of the FSG reduction after The present study has several limitations with respect to trial design.
As discussed above, titration of glargine is an important potential confounding factor in trials that include a flexible insulin dosing strategy.
Compliance with the TTT algorithm did not suggest any relevant differences between the groups with respect to using this dosing algorithm.
Hypoglycaemia risk may have affected dose titration in both groups similarly, despite significant difference in HbA1c. Although the present study did not compare the dulaglutide/glargine regimen with other available treatment options for this study population (eg, addition of prandial insulin or a short-acting GLP-1RA), these data are important for an objective assessment of the combination therapy.
In conclusion, combination of once-weekly dulaglutide 1.5 mg with basal insulin glargine provides an effective and safe treatment option for patients with T2D already treated with basal insulin but who have hyperglycaemia and HbA1c concentration above their target range. and, as such, take responsibility for the integrity of the data and the accuracy of the data analysis. All authors participated in critical reviewing and interpreting the data for the manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.
